As of Jun 3, 2026, the Incyte stock's PE ratio is 13.44. This results from the current EPS of $7.29 and stock price of $97.98. The P/E ratio has decreased by 6% from the past four quarters average of 14.3.
The PE ratio of Incyte has averaged 85.49 over the last ten years. The current PE ratio of 13.44 is 84% below the historical average. In the past ten years, INCY's PE ratio was at its highest in the Dec 2024 quarter at 431.69, when the stock price was $69.07 and the EPS was $0.16. The lowest value was in the Mar 2026 quarter, when it reached 12.91 with a price of $94.12 and an EPS of $7.29.
Maximum annual increase: 1,735.42% in 2024
Maximum annual decrease: -96.53% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 14.99 | -96.53% | $98.77 | $6.59 |
| 2024 | 431.69 | 1,735.42% | $69.07 | $0.16 |
| 2023 | 23.52 | -55.2% | $62.79 | $2.67 |
| 2022 | 52.5 | 207.56% | $80.32 | $1.53 |
| 2021 | 17.07 | N/A | $73.4 | $4.3 |
| 2020 | N/A | N/A | $86.98 | -$1.36 |
| 2019 | 41.98 | -65.67% | $87.32 | $2.08 |
| 2018 | 122.29 | N/A | $63.59 | $0.52 |
| 2017 | N/A | N/A | $94.71 | -$1.53 |
| 2016 | 182.31 | -93.28% | $100.27 | $0.55 |
| 2015 | 2,711.25 | N/A | $108.45 | $0.04 |
| 2014 | N/A | N/A | $73.11 | -$0.29 |
| 2013 | N/A | N/A | $50.63 | -$0.56 |
| 2012 | N/A | N/A | $16.61 | -$0.34 |
| 2011 | N/A | N/A | $15.01 | -$1.49 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 12.91 | -13.88% | $94.12 | $7.29 |
| Dec 2025 | 14.99 | 6.77% | $98.77 | $6.59 |
| Sep 2025 | 14.04 | -8.89% | $84.81 | $6.04 |
| Jun 2025 | 15.41 | -92.62% | $68.1 | $4.42 |
| Mar 2025 | 208.79 | -51.63% | $60.55 | $0.29 |
| Dec 2024 | 431.69 | 11.03% | $69.07 | $0.16 |
| Sep 2024 | 388.82 | 143.73% | $66.1 | $0.17 |
| Jun 2024 | 159.53 | 832.38% | $60.62 | $0.38 |
| Mar 2024 | 17.11 | -27.25% | $56.97 | $3.33 |
| Dec 2023 | 23.52 | -23.06% | $62.79 | $2.67 |
| Sep 2023 | 30.57 | -19.47% | $57.77 | $1.89 |
| Jun 2023 | 37.96 | -23.31% | $62.25 | $1.64 |
| Mar 2023 | 49.5 | -5.71% | $72.27 | $1.46 |
| Dec 2022 | 52.5 | 211.94% | $80.32 | $1.53 |
| Sep 2022 | 16.83 | -5.4% | $66.64 | $3.96 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, INCY's PE ratio is lower than the 3, 5 and 10-year averages.
With a P/E of 13.44, INCY stands below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 23.02, Incyte's P/E is 42% lower.
INCY's PE ratio is lower than its peer stocks LLY and NVS. Incyte's current PE ratio of 13.44 is below the average of its peers, which is 26.22.
| Stock name | PE ratio | Market cap |
|---|---|---|
| INCY Incyte Corp | 13.89 | $20.24B |
| PFE Pfizer Inc | 19.61 | $146.42B |
| NVS Novartis AG | 21.14 | $283.17B |
| AMGN Amgen Inc | 23.87 | $186.56B |
| LGND Ligand Pharmaceuticals Inc | 29.83 | $4.72B |
| LLY ELI LILLY & Co | 39.88 | $1.06T |
| ARDX Ardelyx Inc | N/A | $1.34B |
| GERN Geron Corp | N/A | $769.83M |
INCY stock has a price to earnings ratio of 13.44 as of Jun 3, 2026.
As an average over the last 3 years, INCY stock has a PE ratio of 112.95.
As an average over the last 5 years, INCY stock has a PE ratio of 80.54.
Over the last ten years, the quarterly PE ratio reached a historic high of 431.69 in the Dec 2024 quarter.
INCY's price to earnings ratio is currently 84% below its 10-year historical average.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Jun 3, 2026), Incyte's stock price is $97.98. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $7.29. Therefore, Incyte's P/E ratio for today is 13.44. PE RATIO(13.44) = STOCK PRICE($97.98) / TTM EPS($7.29)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.